Form 4: Abbott SVP Orville Receives Restricted Stock Award

Abbott Laboratories Senior Vice President Jacob A. Orville was granted 13,255 restricted common shares as part of the company's 2017 Incentive Stock Program.

Summary

• Jacob A. Orville, Senior Vice President of Abbott Laboratories (ABT), acquired 13,255 common shares without par value.
• The acquisition occurred on March 23, 2026, at an acquisition price of $0 per share, indicating a grant rather than a purchase.
• These shares represent a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program.
• The award has a 2-year term, with half of the award vesting annually, beginning on March 23, 2027.
• The award includes the right for shares to be withheld for tax purposes.
• Following this transaction, Mr. Orville beneficially owns 50,493 common shares.
• The Form 4 filing was signed on March 25, 2026, by Jessica H. Paik, Attorney-in-Fact for Jacob A. Orville.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive incentive practices that align management interests with long-term company performance, without indicating any significant new developments.

Positives

• The restricted stock award aligns the Senior Vice President's long-term interests with those of shareholders, incentivizing sustained company performance.
• This grant serves as a retention mechanism for key executive talent within Abbott Laboratories.

Negatives

• The grant of new shares, while part of an approved program, represents a minor potential for dilution to existing shareholders.

Risks

• The restricted stock award is subject to a vesting schedule, meaning the shares could be forfeited if employment terminates before the vesting conditions are met.

Future Outlook

The restricted stock award is structured with a 2-year vesting term, with half of the shares vesting annually starting March 23, 2027, indicating a future commitment and incentive for the executive.

Industry Context

StockSavvy.ai notes that restricted stock awards are a common component of executive compensation packages across various industries, particularly in large, established companies like Abbott Laboratories. These awards are designed to align executive incentives with long-term shareholder value creation and to promote executive retention.

Comparison to Industry Standards

• The use of restricted stock awards with multi-year vesting schedules is a standard practice in executive compensation, comparable to programs at peer companies in the healthcare and pharmaceutical sectors such as Johnson & Johnson (JNJ) and Medtronic (MDT).
• The grant of shares at a $0 acquisition price is typical for incentive-based awards, reflecting compensation rather than a direct purchase.

Related Party Transactions

• The restricted stock award to Senior Vice President Jacob A. Orville constitutes a related party transaction, as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: The grant aligns executive incentives with long-term shareholder value, potentially leading to improved company performance, though it involves minor share dilution.
• Employees: Demonstrates the company's commitment to competitive executive compensation and retention strategies.
• Management: Provides a significant long-term incentive tied to the company's stock performance and continued employment.

Next Steps

• The restricted shares will vest in two tranches, with the first half vesting on March 23, 2027, and the second half vesting on March 23, 2028 (assuming a 2-year term with 1/2 vesting annually).

Key Dates

Recommendation

This Form 4 filing reports a routine restricted stock grant to a senior executive, which is a standard part of compensation and does not present new information that would fundamentally alter the investment thesis for Abbott Laboratories. The transaction is expected and does not indicate any significant operational or financial changes that would warrant a change from a 'hold' recommendation.

Keywords

Abbott Laboratories, ABT, Restricted Stock Award, Executive Compensation, Insider Transaction, Form 4, Stock Grant, Corporate Governance